Leprosy Downgrading Reaction Associated With Griseofulvin

Shulman, D. Geoffrey

doi:10.1001/archderm.1982.01650230037024

Cited by 5 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Já aquela do tipo downgrading reaction, ocorre naqueles pacientes não tratados, caracterizando-se pelo aumento da carga bacilar, aumento nos níveis de anticorpos, cursam com negativação do Mitsuda, em suma, manifesta-se uma piora da resposta imunológica com expressão da resposta Th2 e evolução em direção ao polo V, instalando-se a imunossupressão nesses indivíduos, o que torna essa reação favorável à multiplicação bacilar (SHULMAN;NGUYEN, 1982;GOHAR, 2014).…”

Section: Poliquimioterapia Padrãounclassified

Relações causais entre os antígenos de M. leprae (LAM E PGL-1) e os receptores TOLL-LIKE 1, 2 e seus efeitos na expressão de citocinas IFN-γ e IL-10 nas reações hansênicas

Antunes¹

View full text Add to dashboard Cite

Background: The leprosy reactions are acute immunological events that occur before, during or after MDT of leprosy, being triggered mainly by interaction between the antigens of Mycobacterium leprae, PGL-1 and LAM, with the components of immunity of the host, such as, TLR1 and TLR2, that induce cells to produce cytokines related to control or bacillary dissemination. Objectives: The main goal of this research is establish causal relations between antigens of M. leprae (PGL-1 and LAM) and receptors, TLR1, TLR2 and their effects on cytokines expression, IFN-10, in leprosy reactions. Methods: Through ELISA serology it was possible measure the levels of anti-PGL-1 IgM and anti-LAM IgG, and with the use of the RT-qPCR proceeded the analysis of gene expression of TLR1 TLR2, IFN-10 using blood samples from 17 reactional patients and 17 nonreactional patients (Case-control study) that posteriorly were subdivided into 4 groups. For comparison between means of the variables, it resorted to use of analysis of variance (ANOVA) and about the degree of association between the variables, it has applied the correlation matrix. At the end, it was used the path analysis to verify the causal relation evolving antigens and toll-like receptors, whose the direct and indirect effects were the cytokines expression. Results: Among 34 patients, 76.4% (26/34) were MB and 23.6% PB, being that 100% (17/17) of reactional cases were MB and among the controls 53% (9/17). Analyzing the reactional group, 41.2% (7/17) suffered type 1 reaction, while 58.8% (10/17) presented type 2 reaction, emphasizing that, among patients with type 1 reaction, 57.1% (4/7) had reaction before treatment (downgrading), 14.2% (1/7) during and 28.8% (2/7) after MDT, whereas all patients of the type 2 reaction group, developed this occurrence after treatment. The levels of anti-PGl-1 have been elevated in type 1 and type 2 reactions with significant differences between means of these groups when compared to PB controls (F=6.42; p=0.002). Regarding to anti-LAM, this has been associated to type 2 reaction, group whose the means were higher than others, and this data showed significant differences as well (F=15.27; p<0.001). The reactional groups expressed higher levels of IL-10 (F=3.99; p=0,023), whereas the control group produced high levels of IFN-, especially the PB control (F=5.30; p=0.008). There were no differences in the levels of TLR1 and TLR2 expression in the comparison among groups. In the reactional group, the path analysis quantified the direct effects of anti-LAM (0.623) e anti-PGL-1 (0.605) on TLR2, which were higher than the residual effect of this model (0.255), indicating that these antigenic markers influenced only the TLR2 expression, which consequently correlated with the IL-10 expression in this group. An opposing mechanism occurred in the control group, insofar as it was found an immunological pathway that regulated the IFN-expression dependent on TLR1 and TLR2 association. Conclusion: In conclusion, path analysis allowed to demonstrate the causal r...

show abstract

Section: Poliquimioterapia Padrãounclassified